Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.71 |
| ▸ | KMO | O15229 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 4/20 | 0.57 |
| ▸ | RXRB | P28702 | 4/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756311 | 1.00 | BCL2 (0.71) | BCL2KMOALDH1A1LMNAGAA | |
| SCHEMBL12894987 | 0.88 | BCL2 (0.78) | BCL2KMOLMNAGAARXRA | |
| SCHEMBL850998 | 0.87 | KMO (0.61) | BCL2KMOALDH1A1LMNAGAA | |
| SCHEMBL18798550 | 0.87 | BCL2 (0.58) | BCL2KMOLMNAGAAEPHX2 | |
| SCHEMBL1623879 | 0.86 | BCL2 (0.57) | BCL2DHFRPTGS2 | |
| SCHEMBL15214997 | 0.86 | BCL2 (0.57) | BCL2DHFRPTGS2 | |
| SCHEMBL28369469 | 0.86 | BCL2 (0.75) | BCL2KMOALDH1A1RXRARXRB | |
| SCHEMBL14683877 | 0.85 | KMO (0.87) | KMOLMNAGAARXRARXRB | |
| SCHEMBL29577419 | 0.85 | KMO (0.87) | KMOLMNAGAARXRARXRB | |
| SCHEMBL10243641 | 0.85 | BCL2 (0.55) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196373-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-02-05 | — | — | US | disclosed |
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-8846707-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein | UNIVERISTY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2012018868-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | STAT3, STAT1, STAT4 | BCL2 101/4885KMO 1159/4885ALDH1A1 4285/4885 |
| US-10196373-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | STAT3, STAT1, STAT4 | BCL2 101/4885KMO 1159/4885ALDH1A1 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.